It's worth mentioning that to date, two IL-6 inhib
Post# of 155038
(Total Views: 886)
Posted On: 06/18/2020 12:11:33 PM
It's worth mentioning that to date, two IL-6 inhibitors Actemra and Kevzara (while kevzara lowered crp in it's study) have failed to produce meaningful clinical improvements in severe and critical patients.
This is important because 1) it lends credibility to Dr P and Dr L's statements about piecemeal approaches being ineffective and 2) it confirms that pro inflammatory cytokines are only part of the puzzle. If IL-6 targeted therapy was all that was necessary to prevent mortality then both drugs should have worked.
Once the disease progresses to the immunological, systemic phase rantes has already played a part in trafficking immune cells to different locations in the body. At that point anything targeting single cytokine just isn't enough.
I'm curious to see the effect of GMCSF targeted therapies. But if DR BP and L were right about IL-6 then they're probably right about GMCSF, piecemeal.
The more data that comes out the more I'm convinced Leronlimab is one of the most if not the most effective treatment all around.
This is important because 1) it lends credibility to Dr P and Dr L's statements about piecemeal approaches being ineffective and 2) it confirms that pro inflammatory cytokines are only part of the puzzle. If IL-6 targeted therapy was all that was necessary to prevent mortality then both drugs should have worked.
Once the disease progresses to the immunological, systemic phase rantes has already played a part in trafficking immune cells to different locations in the body. At that point anything targeting single cytokine just isn't enough.
I'm curious to see the effect of GMCSF targeted therapies. But if DR BP and L were right about IL-6 then they're probably right about GMCSF, piecemeal.
The more data that comes out the more I'm convinced Leronlimab is one of the most if not the most effective treatment all around.
(7)
(0)